Valuation: Sionna Therapeutics, Inc.

Market Cap 175M 157M 144M 131M 244M 16.61B 249M 1.72B 690M 8.74B 657M 643M 27.56B P/E 2026 *
-1.6x
P/E 2027 * -1.68x
Enterprise Value 19.58M 17.54M 16.13M 14.62M 27.32M 1.86B 27.84M 192M 77.23M 978M 73.49M 71.93M 3.08B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.12%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Sionna Therapeutics, Inc.

1 day-3.25%
1 week+7.50%
Current month-26.43%
1 month-26.43%
3 months-91.73%
6 months-90.00%
Current year-90.59%
1 week 3.57
Extreme 3.57
4.16
1 month 3.55
Extreme 3.55
5.19
Current year 3.55
Extreme 3.55
54.97
1 year 3.55
Extreme 3.55
54.97
3 years 3.55
Extreme 3.55
54.97
5 years 3.55
Extreme 3.55
54.97
10 years 3.55
Extreme 3.55
54.97
Manager TitleAgeSince
Corporate Officer/Principal - 01/08/2019
Corporate Officer/Principal - 01/08/2019
Chief Executive Officer 55 01/05/2021
Director TitleAgeSince
Director/Board Member 51 01/12/2019
Director/Board Member 44 01/12/2019
Director/Board Member 52 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
17/09/26 Free

General Counsel

262,545 0.5807%
17/09/26 Free

Chief Financial Officer

425,417 0.9409%
17/09/26 Free

Chief Technology Officer

411,400 0.9099%
Change 5-day change 1-year change 3-year change Capi.($)
-3.25%+7.50%-89.82% - 175M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -0.02%+7.54%+34.09%+206.32% 39.45B
Weighted average by Cap. +0.18%+5.44%+48.44%+186.13%

Financials

2026 *2027 *
Net sales - -
Net income -112M -100M -92.29M -83.62M -156M -10.64B -159M -1.1B -442M -5.6B -420M -411M -17.65B -114M -102M -93.74M -84.94M -159M -10.8B -162M -1.12B -449M -5.68B -427M -418M -17.92B
Net Debt -155M -139M -128M -116M -217M -14.75B -221M -1.53B -613M -7.76B -583M -571M -24.48B -231M -207M -190M -172M -322M -21.91B -328M -2.27B -910M -11.52B -866M -847M -36.34B
Projected Income Statement - Annual - Sionna Therapeutics, Inc.
Logo Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Employees
59
Date Price Change Volume
30/10/26 $3.870 -3.25% 534,379
29/10/26 $4.000 -0.99% 578,363
28/10/26 $4.040 +4.39% 952,997
27/10/26 $3.870 +4.88% 1,000,697
26/10/26 $3.690 +2.50% 614,224
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Sionna Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
3.870USD
Average target price
21.00USD
Spread / Average Target
+442.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sionna Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SION Stock